Sai Hong Ou, MD
Hematology & Oncology · Orange, CANPI 1639259872
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (42.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 21.5%. Reporting peaked in 2019 at $94,002 and has fallen 98.8% since, to $1,170 in 2025. Among hematology & oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 183 payments — averaging $1075.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$42K
- Takeda Pharmaceuticals U.S.A., Inc.$27K
- AstraZeneca$23K
- Merck$18K
- Johnson & Johnson$9K
- Daiichi Sankyo Inc.$8K
- plus $69K from 20 others
Across 463 payments — averaging $14,439 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$2M
- Janssen Research & Development, LLC$1.5M
- Genentech, Inc.$577K
- Eli Lilly$481K
- Daiichi Sankyo Inc.$363K
- Mirati Therapeutics, Inc.$278K
- plus $1.5M from 16 others
What the payments were for
- Consulting fees$82,92242%
- Speaking & faculty fees$77,91540%
- Travel & lodging$30,84216%
- Food & beverage$4,8852%
- Education$2550%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 38 | $42,373 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $27,323 |
| AstraZeneca | 26 | $22,548 |
| Merck | 6 | $18,295 |
| Johnson & Johnson | 10 | $9,349 |
| Daiichi Sankyo Inc. | 12 | $7,956 |
| Janssen Scientific Affairs, LLC | 8 | $7,953 |
| Genentech USA, Inc. | 18 | $7,788 |
| Janssen Global Services, LLC | 6 | $7,430 |
| Eisai Inc. | 11 | $6,791 |
| F. Hoffmann-la Roche AG | 5 | $6,515 |
| Beigene USA, Inc. | 1 | $6,500 |
| Blueprint Medicines Corporation | 3 | $6,189 |
| Bayer | 4 | $4,758 |
| Sanofi | 1 | $2,916 |
| Lilly USA, LLC | 1 | $2,800 |
| Janssen Research & Development, LLC | 1 | $2,160 |
| Foundation Medicine, Inc. | 3 | $2,145 |
| Mirati Therapeutics, Inc. | 1 | $1,500 |
| E.r. Squibb & Sons, L.L.C. | 2 | $1,318 |
| Astrazeneca UK Limited | 8 | $1,147 |
| EMD Serono, Inc. | 1 | $500 |
| Pfizer Corporation Hong Kong Limited | 1 | $320 |
| Regeneron Healthcare Solutions, Inc. | 2 | $121 |
| AbbVie | 2 | $85 |
| Karyopharm Therapeutics Inc. | 3 | $37 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LORBRENA$33,852
- ALUNBRIG$22,923
- TAGRISSO$21,846
- Alecensa$10,130
- RYBREVANT$10,088
- XALKORI$8,130
- TECENTRIQ$7,220
- LENVIMA$6,475
- BRAFTOVI$4,480
- VIZIMPRO$4,480
- MEKTOVI$4,480
- Non-Covered Product$2,923
- Enhertu$2,055
- FOUNDATIONONE LIQUID$2,000
- FOUNDATIONFOCUS$2,000
- FOUNDATIONONE CDX$2,000
- FOUNDATIONONE HEME$2,000
- FOUNDATIONONE$2,000
- Vitrakvi$1,905
- KRAZATI$1,500
How this compares
$196,819 in reported general payments places this provider in the 95th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 124 | $2,134,100 |
| RetevmoSelpercatinib | 27 | $620,379 |
| AlecensaAlectinib Hcl | 21 | $387,022 |
| GilotrifAfatinib Dimaleate | 26 | $266,680 |
| RozlytrekEntrectinib | 11 | $194,986 |
| IressaGefitinib | 24 | $174,630 |
| EliquisApixaban | 24 | $19,717 |
| Demeclocycline Hcl | 11 | $2,964 |
| Megestrol Acetate | 20 | $1,148 |
| Sodium Chloride0.9 % Sodium Chloride | 25 | $866 |
| Dexamethasone | 46 | $364 |
| Potassium Chloride | 14 | $323 |
| Ondansetron Hcl | 29 | $246 |
| Prochlorperazine Maleate | 15 | $173 |
| Furosemide | 15 | $40 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso, Iressa | $22,548 | $2,308,730148 claims |
| Lilly USA, LLCRetevmo, Olanzapine | $2,800 | $620,40148 claims |
| Genentech USA, Inc.Alecensa, Rozlytrek | $7,788 | $582,00832 claims |
| PfizerEliquis | $42,373 | $19,71724 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Orange
- Catherine CoombsOrange$786K
- Arash Rezazadeh KalebastyOrange$516K
- Misako NagasakaOrange$507K
- Elizabeth BremOrange$335K
- May ChoOrange$334K
- Angela FleischmanOrange$255K
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.